^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BCMA targeted CAR T

i
Other names: BCMA targeted CAR T, BCMA-specific CAR-expressing T lymphocytes, anti-BCMA-CAR-transduced T cells
Associations
Trials
Company:
Fred Hutchinson Cancer Center
Drug class:
BCMA-targeted CAR-T immunotherapy
Related drugs:
Associations
Trials
11ms
NCI-2018-00514: BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma (clinicaltrials.gov)
P1, N=19, Terminated, Fred Hutchinson Cancer Center | Active, not recruiting --> Terminated; Closed per SRC Low Accrual Policy
Trial termination • Combination therapy • CAR T-Cell Therapy • IO biomarker
|
SDC1 (Syndecan 1)
|
cyclophosphamide • fludarabine IV • BCMA targeted CAR T • crenigacestat (LY3039478)
11ms
Enrollment closed • Combination therapy • CAR T-Cell Therapy • IO biomarker
|
SDC1 (Syndecan 1)
|
cyclophosphamide • fludarabine IV • BCMA targeted CAR T • crenigacestat (LY3039478)
1year
Journal • CAR T-Cell Therapy
|
CD20 (Membrane Spanning 4-Domains A1) • IFNG (Interferon, gamma)
|
CD20 positive
|
BCMA targeted CAR T
over1year
NCI-2018-00514: BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma (clinicaltrials.gov)
P1, N=18, Suspended, Fred Hutchinson Cancer Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2025
Trial completion date • Trial primary completion date • Combination therapy • CAR T-Cell Therapy
|
SDC1 (Syndecan 1)
|
cyclophosphamide • fludarabine IV • BCMA targeted CAR T • crenigacestat (LY3039478)
over2years
NCI-2018-00514: BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma (clinicaltrials.gov)
P1, N=18, Suspended, Fred Hutchinson Cancer Center | Trial completion date: Apr 2022 --> Sep 2025 | Trial primary completion date: Apr 2022 --> Sep 2024
Trial completion date • Trial primary completion date • Combination therapy • CAR T-Cell Therapy
|
SDC1 (Syndecan 1)
|
cyclophosphamide • fludarabine IV • BCMA targeted CAR T • crenigacestat (LY3039478)
over2years
Stromal cell derived IL6 inhibits the extrinsic apoptotic pathway in multiple myeloma cell lines (AACR 2022)
Clinical trials have shown that BCMA targeted CAR-T therapy induces MM remission in most patients with heavily pretreated relapsed refractory MM; however, the duration of the response has been disappointing...This suggests that soluble factors in the BMM can convert cells from type I to type II (mitochondrial-dependent) death receptor signaling and that inhibiting BMM signals such as IL6 may enhance FASL-induced cell death in MM. However, the data also demonstrate that the role of FAS in CAR-T killing is cell context dependent.
Preclinical • IO biomarker
|
IL6 (Interleukin 6) • FASLG (Fas ligand) • GZMB (Granzyme B) • FAS (Fas cell surface death receptor)
|
BCMA targeted CAR T
3years
Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma (ASH 2021)
We have completed accrual to a phase 1 first-in-human trial of escalating doses of BCMA targeted CAR T cells in combination with a GSI (JSMD194) for patients with relapsed or refractory multiple myeloma, and herein report results on the 18 patients accrued to this trial. From June 2018 to March 2021, 18 patients underwent leukapheresis, run-in with JSMD194, and treatment with BCMA CAR T cells. The median age was 65 years, and patients had received a median of 10 prior lines of therapy (range, 4-19). 67% of patients were refractory to lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, 72% had high-risk cytogenetic features, and 28% had extramedullary disease.
Clinical • Combination therapy • CAR T-Cell Therapy • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • SDC1 (Syndecan 1)
|
lenalidomide • bortezomib • Darzalex (daratumumab) • carfilzomib • pomalidomide • BCMA targeted CAR T • crenigacestat (LY3039478)